ClinicalTrials.gg
CompletedNCT00699192Updated Jun 6, 2011Results posted

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

A Phase 3 interventional study of Amlodipine 5 mg and Valsartan 80 mg in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in 10 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2011-06-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
965
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
20th of 139
965 · median 198
Started
2008
with 6 others
Phase 3
53 of 140
none open now
Registered
93rd of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 20th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2008, is one of 53 in phase 3, and was the 93rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

To characterize the safety, tolerability, and efficacy profile of amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 mg (with optional titration to 5/80 mg) and amlodipine 5 mg monotherapy in elderly patients (≥ 65 years of age) with essential hypertension. All three regimens are expected to be well tolerated.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood pressure
  • hypertension
  • elderly
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written before any assessment was performed.
  • Male or female at least 65 years of age.
  • Diagnosed as having hypertension:

    • At Visit 1/Screening, treatment naïve patients had to have a mean seated SBP ≥ 155 mmHg and \< 180 mmHg; patients undergoing washout from their previous antihypertension medication had to have a mean seated SBP \<180 mmHg.
    • At Visit 2/Single-blind run-in entry, all patients had to have a mean seated SBP ≥ 155 mmHg and \< 180 mmHg.
    • At Visit 3/Core double-blind treatment period entry, all patients had to have a mean seated SBP ≥ 145 mmHg and \< 180 mmHg.
  • Ability to communicate and comply with all study requirements including measuring their blood pressure at home, daily as instructed, using the home blood pressure monitor provided by the Sponsor.
  • Female patients had to be for at least one year.

Exclusion criteria

Exclusion criteria

  • Severe hypertension (mean seated SBP ≥ 180 mmHg and/or a mean seated DBP ≥ 110 mmHg).
  • History of secondary hypertension (including primary aldosteronism, renovascular hypertension, pheochromocytoma, etc.).
  • Use of three or more antihypertensive drugs. Dual fixed dose combination therapy was considered as two antihypertensive drugs.
  • Administration of any agent indicated for the treatment of hypertension after Visit 1, with the permitted exception of those antihypertensive medications requiring tapering down (e.g. beta-blocker and/or clonidine) commencing with Visit 1.
  • Known moderate or malignant retinopathy. Moderate was defined as retinal signs of hemorrhage, microaneurysm, cotton-wool spot, hard exudates, or a combination thereof; malignant defined as signs of moderate retinopathy plus swelling of the optic disk.
  • Known or suspected , including history of allergy or to angiotensin receptor blockers (ARB), calcium channel blockers (CCB), or to drugs with similar chemical structures.
  • History of cerebrovascular accident, thrombotic stroke, or .
  • Significant history of coronary artery disease (CAD) such as any history of myocardial infarction (MI), angina pectoris, and all types of revascularization procedures.
  • History of or diagnosis of congestive heart failure Grade II-IV according to the (NYHA) classification.
  • valvular heart disease.
  • All patients with Type 1 diabetes mellitus and those patients with Type 2 diabetes mellitus who, in the opinion of the investigator, were not well controlled. Patients who needed oral anti-diabetic medication to adequately control their Type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to Visit 1.
  • Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia.
  • Second or third degree heart block with or without a pacemaker.
  • Significant hepatic disease, as demonstrated by any one of the following: (AST) or alanine aminotransferase (ALT) values greater than two times the at Visit 1, a history of hepatic encephalopathy, a history of esophageal varices, or a history of a portocaval shunt.
  • Evidence of renal impairment as determined by any one of the following: (GFR) \< 50 ml/min/1.73m2 as measured by the Modification of Diet in Renal Disease (MDRD) formula at Visit 1, a history of dialysis, or a history of nephrotic syndrome.
  • History of clinically significant allergies including asthma and/or multiple drug allergies.
  • Any surgical or medical condition with the potential to significantly alter the absorption, distribution, metabolism, or excretion of any drug including but not limited to any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active or inactive inflammatory bowel syndrome within 12 months prior to Visit 1, currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction regarded as clinically meaningful by the investigator.
  • Any condition, not identified in the protocol, that, in the opinion of the investigator or the Novartis monitor, placed the patient at higher risk from his/her participation in the study, or was likely to prevent the patient from complying with the requirement of the study or completing the trial period.
  • History of of any organ system, treated or untreated, within the past 5 years whether or not there was evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin.
  • Any chronic inflammatory condition needing chronic anti-inflammatory therapy.
  • History of drug or alcohol abuse within the last 2 years.
  • Use of drugs at the time of enrollment, or within 30 days prior to Visit 1 (Week 8).
  • Inability to communicate and comply with all study requirements including the unwillingness or inability to provide .
  • Persons directly involved in the execution of this protocol.
  • History of non-compliance to medical regimens, or patients unwilling to comply with the study protocol.
  • Any severe, life-threatening disease within the past five years.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
965 participants (actual)

Study arms

  • Experimental
    Amlodipine/Valsartan 5/80 mg

    1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily

    Drug: Amlodipine 5 mg · Drug: Valsartan 80 mg

  • Active comparator
    Amlodipine/Valsartan 5/40 mg

    1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily

    Drug: Amlodipine 5 mg · Drug: Valsartan 40 mg

  • Active comparator
    Amlodipine 5 mg

    1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily

    Drug: Amlodipine 5 mg · Drug: Placebo

Interventions

  • 1 capsule amlodipine 5 mg orally once daily

  • 1 capsule valsartan 80 mg orally once daily

  • 1 capsule valsartan 40 mg orally once daily

  • DrugPlacebo

    1 capsule placebo to match valsartan orally once daily

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

    At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

    At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

  2. Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 8

    A systolic blood pressure response was defined as a msSBP \< 140 mmHg or ≥ 15 mmHg reduction from baseline at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.

    Time frame: Baseline to end of study (Week 8)

  3. Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)

    Systolic blood pressure control was defined as a msSBP \< 140 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.

    Time frame: End of study (Week 8)

  4. Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)

    Overall blood pressure control was defined as a msSBP \< 140 mmHg and msDBP \< 90 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.

    Time frame: End of study (Week 8)

07

Results

Posted Jun 6, 2011

Participant flow

965 patients were enrolled in the study. Of these, 819 met the criteria for entry into the double-blind phase of the study where efficacy and safety were evaluated.

Participant flow — Overall Study
MilestoneAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
Started275272272
Completed259260261
Not completed161211
Withdrew: Missing111
Withdrew: Adverse event943
Withdrew: Abnormal test procedure result(s)001
Withdrew: Lack of efficacy001
Withdrew: Withdrawal by subject324
Withdrew: Administrative problems131
Withdrew: Protocol violation220

Outcome measures

PrimaryChange in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
mmHgAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)-11.1 ± 12.68-12.3 ± 13.23-6.9 ± 14.00
SecondaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings. A negative change from baseline indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
mmHgAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)-4.2 ± 8.04-5.3 ± 8.19-1.7 ± 7.26
SecondaryPercentage of Patients Achieving a Systolic Blood Pressure Response at Week 8

A systolic blood pressure response was defined as a msSBP \< 140 mmHg or ≥ 15 mmHg reduction from baseline at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 8
Percentage of patientsAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 846.048.334.0
SecondaryPercentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)

Systolic blood pressure control was defined as a msSBP \< 140 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)
Percentage of patientsAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)31.337.520.5
SecondaryPercentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)

Overall blood pressure control was defined as a msSBP \< 140 mmHg and msDBP \< 90 mmHg at the end of the study (Week 8). At study entry, blood pressure (BP) was measured in both arms with an automatic BP monitor. The arm with the higher systolic BP reading was used for all measurements throughout the study. At each study visit, 3 separate sitting BPs were obtained 23-26 hours post-dose with at least 2 minutes between measurements and with the cuff fully deflated. Mean BP was automatically calculated from the 3 readings.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
Percentage of patientsAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)30.936.419.0

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine/Valsartan 5/80 mg—5/274 (1.8%)0/274 (0%)
Amlodipine/Valsartan 5/40 mg—2/272 (0.7%)0/272 (0%)
Amlodipine 5 mg—1/272 (0.4%)0/272 (0%)
Most frequent serious events
Most frequent serious events
EventAmlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mg
TachyarrhythmiaCardiac disorders0/2740/2721/272
OphthalmoplegiaEye disorders0/2741/2720/272
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2741/2720/272
Angina pectorisCardiac disorders1/2740/2720/272
Atrial fibrillationCardiac disorders1/2740/2720/272
Back painMusculoskeletal and connective tissue disorders1/2740/2720/272
Lentigo maligna stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2740/2720/272
Cerebrovascular accidentNervous system disorders1/2740/2720/272
Hypertensive crisisVascular disorders1/2740/2720/272

Baseline characteristics

Age Continuous
Age Continuous(years)Amlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mgTotal
Mean71.8 ± 5.0171.6 ± 5.3871.4 ± 5.4471.6 ± 5.27
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine/Valsartan 5/80 mgAmlodipine/Valsartan 5/40 mgAmlodipine 5 mgTotal
Female152138142432
Male123134130387
08

Study locations

18 sites
  • Novartis Investigative site
    Brno, Czech Republic
  • Investigative site Czech Republic
    Chrudim, Czech Republic
  • Investigative sites Czech Repbulic
    Hodonin, Czech Republic
  • Investigative site Czech Repbulic
    Jicin, Czech Republic
  • Sites in Czech Republic
    Nachod, Czech Republic
  • Investigative sites Czech Republic
    Praha, Czech Republic
  • Investigative site Finland
    Helsinki, Finland
  • Investigative site Finland
    Joensuu, Finland
  • Investigative site Finland
    Kerava, Finland
  • Investigative site Finland
    Tampere, Finland
  • Investigative site France
    Paris, France
  • Investigative site Germany
    Berlin, Germany
  • Investigative site Hungary
    Budapest, Hungary
  • Investigative site Italy
    Rome, Italy
  • Investigative site Poland
    Warsaw, Poland
  • Investigative site Slovakia
    Bratislava, Slovakia
  • Investigative site Spain
    Valencia, Spain
  • Investigative site Sweden
    Malmo, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2008
First posted
Jun 17, 2008
Start
May 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jun 6, 2011
Last update
Jun 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00699192
First posted
Jun 17, 2008
Start date
May 2008
Primary completion
May 2009
Completion
May 2009
Results posted
Jun 6, 2011
Last update
Jun 6, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion